Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia

Objectives Acute undifferentiated leukemia (AUL) is a clinical rare leukemia with an overall poor prognosis. Currently, there are no well-established treatment guidelines for AUL, further exploration of optimal treatment options is now required.Methods We report an AUL patient who was complicated by...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu Cui, Ruihua Mi, Lin Chen, Lin Wang, Dongbei Li, Xudong Wei
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Hematology
Subjects:	Acute undifferentiated leukemia (AUL) Venetoclax Azacitidine B-cell lymphoma-2
Online Access:	https://www.tandfonline.com/doi/10.1080/16078454.2023.2293494
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia
by: Xushu Zhong, et al.
Published: (2024-12-01)

Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination
by: Daniela Taurino, et al.
Published: (2021-08-01)

The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID
by: Antonio Cristiano, et al.
Published: (2022-04-01)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
by: Jenna L. Carter, et al.
Published: (2025-01-01)

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
by: Xin Wang, et al.
Published: (2024-12-01)

Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis
by: Hongbo He, et al.
Published: (2024-12-01)

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
by: Lauro Fabián Amador-Medina, et al.
Published: (2024-12-01)

Venetoclax and Azacitidine Combination is an Effective Salvage Regimen for Fit Patients with IDH-2-mutated Acute Myeloid Leukemia Refractory to Conventional Induction Chemotherapy
by: Musa Fares Alzahrani
Published: (2024-12-01)

AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH.
by: Pasquale Niscola
Published: (2014-02-01)

Complete Remission Obtained with Azacitidine in a Patient with Concomitant Therapy Related Myeloid Neoplasm and Pulmonary Mucormycosis
by: Saveria Capria, et al.
Published: (2013-07-01)

Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center
by: Ziyi Hao, et al.
Published: (2024-12-01)

Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
by: Cheng-Yu Tang, et al.
Published: (2023-10-01)

Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax
by: Claudio Fozza
Published: (2024-01-01)

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
by: Jingying Cui, et al.
Published: (2024-12-01)

First case of acute promyelocytic leukemia with TFG-RARA achieved complete remission treated with venetoclax and all-trans retinoic acid
by: Li Zhu, et al.
Published: (2024-12-01)

A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
by: Elena Elli, et al.
Published: (2012-01-01)

A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
by: Elena Elli, et al.
Published: (2012-03-01)

The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
by: Fei Xin, et al.
Published: (2024-12-01)

Clinico-hematological and immunophenotypic profile of acute leukemia of ambiguous lineage: A four year experience from a single tertiary care centre of West India
by: Varnika Rai, et al.
Published: (2023-07-01)

Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review
by: Xuelian Jin, et al.
Published: (2025-01-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases
by: Enrico Derenzini, et al.
Published: (2024-12-01)

Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation
by: Emiko Kashima, et al.
Published: (2024-12-01)

Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
by: Juan Li, et al.
Published: (2025-12-01)

SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY
by: Naciye Nur Tozluklu, et al.
Published: (2024-12-01)

SPECTRUM AND IMMUNOPHENOTYPIC PROFILE OF ACUTE LEUKEMIA: A TERTIARY CENTER FLOW CYTOMETRY EXPERIENCE
by: Nishit Gupta, et al.
Published: (2019-02-01)

Successfully treatment of PLZF-RARα positive acute promyelocytic leukemia by Venetoclax combining with decitabine: a case report and literature review
by: Ziwei Zhou, et al.
Published: (2024-12-01)

Effect of hypomethylating agents on prognosis in acute myeloid leukemia patients treated with HAG priming: a systematic review and meta-analysis
by: Jun Li, et al.
Published: (2024-12-01)

Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine
by: Kamel Laribi, et al.
Published: (2019-05-01)

A case report of discordant Chikungunya manifestations in a married couple: From acute undifferentiated fever to fatal sepsis with purpura fulminans
by: Ditthawat Pathomchareansukchai, et al.
Published: (2025-01-01)

miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
by: Yilan Xu, et al.
Published: (2025-02-01)

Undifferentiated uterine sarcoma : experience of a single center
by: Hua Yuan, et al.
Published: (2024-12-01)

Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
by: Renshi Kawakatsu, et al.
Published: (2025-01-01)

Unusual transformation from refractory anemia to chronic myelomonocytic leukemia: a case report.
by: Pasquale Niscola
Published: (2014-08-01)

BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies
by: Mariam Markouli, et al.
Published: (2025-01-01)

Efficacy and safety of the combination of decitabine and CHAG priming regimen in the relapsed or refractory acute myeloid leukemia
by: Yan Wu, et al.
Published: (2024-11-01)

Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
by: Dian Jin, et al.
Published: (2024-07-01)

Undifferentiated Embryonal Sarcoma of the Liver: First Case Reported in Central America
by: Amilcar Antonio Alfaro García, et al.
Published: (2024-11-01)

RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?
by: Antonio Cuneo, et al.
Published: (2019-02-01)

Case report: Primary cardiac undifferentiated sarcoma complicated by esophagus stenosis
by: Yuxin Ge, et al.
Published: (2025-01-01)